The HEXD Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, featuring targeted disruption of the HEXD gene. This loss-of-function model enables detailed investigation of hexosaminidase D, a lysosomal enzyme critical for glycoconjugate catabolism. As a polyclonal pool, it captures population-level heterogeneity, offering a robust system for functional genomics studies without clonal bias.
The HeLa parental line, established from Henrietta Lacks?? cervical adenocarcinoma in 1951, is one of the most extensively used cancer cell lines worldwide. Its epithelial carcinoma origin, rapid proliferation, and well-documented genomic and transcriptomic landscape make it an ideal host for generating knockout models. HeLa cells exhibit dysregulated signaling pathways and are a standard tool in cancer biology, virology, and cell biology, providing a relevant context for studying lysosomal function in transformed cells.
HEXD encodes hexosaminidase D, a lysosomal glycosidase that hydrolyzes terminal N-acetyl-??-D-glucosamine residues from glycoproteins and glycolipids, contributing to glycosaminoglycan degradation and lysosomal catabolism. The enzyme operates within a network of lysosomal hydrolases including HEXA, HEXB, MAN2B1, NEU1, GALNS, and GUSB. Its expression and activity are regulated by the transcription factor TFEB and the mTORC1 kinase complex, which sense nutrient availability and lysosomal stress. HEXD interacts with the mannose-6-phosphate receptor (M6PR) for proper lysosomal targeting and associates with lysosomal membrane proteins LAMP-1 and LAMP-2, as well as cathepsins, to facilitate substrate processing. Downstream, HEXD action generates free N-acetylglucosamine and promotes autophagic substrate clearance, linking glycoconjugate processing to cellular recycling pathways.
Knockout of HEXD in HeLa cells is anticipated to impair glycoconjugate turnover, leading to lysosomal accumulation of undigested substrates and potential disruptions in autophagic flux. This phenotype can be exacerbated by the cancer cell background, where autophagy and lysosomal biogenesis are often altered to support tumor metabolism and stress responses. The model thus provides a unique tool to examine hexosaminidase D function in the context of oncogenic lysosomal adaptation, facilitating studies on how defects in glycoconjugate degradation intersect with cancer cell physiology and may model aspects of lysosomal storage disorders.
These HEXD knockout cells are applicable in diverse research settings, including the dissection of glycosaminoglycan catabolism, autophagy regulation, and lysosomal biogenesis. Common assays include western blotting for HEXD expression, enzyme activity assays using 4-MU-NAG, RT-qPCR for HEXD mRNA quantification, and immunofluorescence for LAMP-1 and LC3 to assess lysosomal and autophagic compartments. More advanced techniques such as LysoTracker staining by flow cytometry, autophagic flux measurements with bafilomycin A1, M6PR co-localization by confocal microscopy, and metabolic labeling of glycoconjugates with azido-sugars are also compatible. The cells serve as a platform for drug screening aimed at lysosomal enzyme modulators and for modeling diseases like mucopolysaccharidoses and neurodegeneration. For further inquiries, please contact Ascent Research.
